AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17275199 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 218
Study 17275199 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status and pack years
Number of subjects: 218
Study 15012784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT)
Number of subjects: 6
Study 15012784 — intervention group
Group type: COMPARATOR
Intervention: No pancreatic enzyme replacement therapy (no PERT)
Number of subjects: 6
Study 15012784 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 6
Study 11675363 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) treatment
Number of subjects: 0
Study 9601155 — intervention group
Group type: EXPERIMENTAL
Intervention: Proctoclysis (rectal hydration) with normal saline or tap water at a rate of 250 +/- 63 cc/hr for 15 +/- 8 days
Number of subjects: 78
Study 9601155 — intervention group
Group type: EXPERIMENTAL
Intervention: Proctoclysis
Number of subjects: 78
Study 9601155 — intervention group
Group type: COMPARATOR
Intervention: Hypodermoclysis
Number of subjects: 78
Study 9601155 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 78
Study 7527181 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 14
Study 7527181 — intervention group
Group type: COMPARATOR
Intervention: Coronary arteriography (CAG)
Number of subjects: 14
Study 3198778 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with a psychologist
Number of subjects: 26
Study 3198778 — intervention group
Group type: COMPARATOR
Intervention: No interviews (control group)
Number of subjects: 26
Study 30835085 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide
Number of subjects: 80
Study 30835085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30702488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg) plus Lansoprazole (30 mg daily)
Number of subjects: 300
Study 30702488 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Lansoprazole (30 mg daily)
Number of subjects: 300
Study 28820909 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured moderate intensity walking, resistance, and flexibility physical activity program
Number of subjects: 1635
Study 28820909 — intervention group
Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 1635
Study 25525195 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of darunavir (DRV600) once daily
Number of subjects: 100
Study 25525195 — intervention group
Group type: COMPARATOR
Intervention: 800 mg of darunavir (DRV800) once daily
Number of subjects: 100
Study 23081681 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*2 or *3 variant allele
Number of subjects: 928
Study 23081681 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*3 allele
Number of subjects: 928
Study 23081681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking among wild-type individuals
Number of subjects: 928
Study 21729811 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5 mg/kg (Group L)
Number of subjects: 165
Study 21729811 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5 mg/kg‐ephedrine 30 μg/kg (Group LE)
Number of subjects: 165
Study 21729811 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 30 μg/kg (Group E30)
Number of subjects: 165
Study 21729811 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 70 μg/kg (Group E70)
Number of subjects: 165
Study 21729811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine groups (E30 and E70)
Number of subjects: 165
Study 19902675 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg) intrauterine
Number of subjects: 200
Study 19902675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17121171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg for 4 weeks followed by sertraline 50 mg to 100 mg for 2 weeks for nonresponders
Number of subjects: 48
Study 17121171 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 48
Study 15371138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-based therapies
Number of subjects: 29
Study 15371138 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing support and intervention
Number of subjects: 29
Study 11401011 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 36
Study 11401011 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.038 mg/kg
Number of subjects: 36
Study 11401011 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 9678817 — intervention group
Group type: COMPARATOR
Intervention: Purified immunoglobulins from hyperimmune bovine colostrum for 1 month
Number of subjects: 24
Study 8053576 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 27
Study 8053576 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 27
Study 3133529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propicillin (3 mega units transorally for 12 days)
Number of subjects: 100
Study 3133529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29946650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-coat combined with composite resin
Number of subjects: 70
Study 29946650 — intervention group
Group type: COMPARATOR
Intervention: Composite resin directly
Number of subjects: 70
Study 28594761 — intervention group
Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 163
Study 28594761 — intervention group
Group type: COMPARATOR
Intervention: Suture
Number of subjects: 163
Study 26576673 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture plus lifestyle modification
Number of subjects: 150
Study 26576673 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 150
Study 23151089 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 100
Study 23151089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 100
Study 22014336 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific hysteroscopic biopsy-induced injury on the posterior endometrium during the D4-D7 period of the controlled ovarian hyperstimulation cycle
Number of subjects: 30
Study 22014336 — intervention group
Group type: COMPARATOR
Intervention: No hysteroscopic biopsy-induced endometrium injury
Number of subjects: 30
Study 18433043 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 58
Study 12663273 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g EPA+DHA/d
Number of subjects: 150
Study 12663273 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 g ALA/d
Number of subjects: 150
Study 12663273 — intervention group
Group type: COMPARATOR
Intervention: n-6 PUFA control
Number of subjects: 150
Study 10217581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg of alum-precipitated mAb 13B8.2
Number of subjects: 158
Study 10217581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 7618705 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (300 micrograms.kg‐1.min‐1 during CPB after bolus of 2 mg/kg prior to CPB)
Number of subjects: 29
Study 7618705 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 29
Study 7618705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2144203 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex and flutamide
Number of subjects: 149
Study 2144203 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 149
Study 345733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 34
Study 345733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30142288 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants receiving financial gratification in advance
Number of subjects: 0
Study 30142288 — intervention group
Group type: COMPARATOR
Intervention: Participants not receiving financial gratification in advance
Number of subjects: 0
Study 27166171 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS (1A‐tDCS)
Number of subjects: 24
Study 27166171 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS (1C‐tDCS)
Number of subjects: 24
Study 27166171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS (2C‐tDCS)
Number of subjects: 24
Study 27166171 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 25884605 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 606
Study 25884605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 23648347 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 27
Study 23648347 — intervention group
Group type: COMPARATOR
Intervention: Non-ASCT
Number of subjects: 27
Study 21210796 — intervention group
Group type: EXPERIMENTAL
Intervention: MassHealth hospital pay-for-performance program
Number of subjects: 62
Study 21210796 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (propensity-score matched)
Number of subjects: 62
Study 18549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation (group R) - 10 sessions including exercises on a stabilometric platform, point de mire, and a series of five exercises repeated five times daily.
Number of subjects: 40
Study 18549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation (group R)
Number of subjects: 40
Study 18549515 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C) - told to 'perform their daily activities'.
Number of subjects: 40
Study 17596639 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver skill building intervention
Number of subjects: 143
Study 17596639 — intervention group
Group type: COMPARATOR
Intervention: Information and support oriented comparison condition
Number of subjects: 143
Study 14756468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg and pseudoephedrine 120 mg twice daily for 2 weeks
Number of subjects: 0
Study 14756468 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg and montelukast 10 mg once daily for 2 weeks
Number of subjects: 0
Study 14756468 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 0
Study 11294481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg for nortriptyline comparator trial; 50-100 mg for fluoxetine comparator trial)
Number of subjects: 0
Study 11294481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 9021962 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3 10 million units (MU) three times a week for 24 weeks
Number of subjects: 77
Study 9021962 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3 lower doses (1.0, 2.5, 5.0 MU)
Number of subjects: 77
Study 9021962 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3
Number of subjects: 77
Study 7997708 — intervention group
Group type: COMPARATOR
Intervention: Standard methods for survival analysis
Number of subjects: 0
Study 7997708 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined estimate of survival using auxiliary information
Number of subjects: 0
Study 29370144 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Proteins (WP) pre-meal (20 g)
Number of subjects: 24
Study 29370144 — intervention group
Group type: COMPARATOR
Intervention: Water (control) pre-meal
Number of subjects: 24
Study 27784290 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (nutrition, physical activity, and mental health)
Number of subjects: 12
Study 27784290 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care (nutrition and physical activity)
Number of subjects: 12
Study 27784290 — intervention group
Group type: COMPARATOR
Intervention: Active Control (non-nutrition, physical activity, or mental health)
Number of subjects: 12
Study 25514542 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-MLR 80 mg capsule or sprinkles
Number of subjects: 26
Study 25514542 — intervention group
Group type: COMPARATOR
Intervention: Ritalin IR 25 mg
Number of subjects: 26
Study 21975593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based eating disorder prevention program
Number of subjects: 481
Study 21975593 — intervention group
Group type: COMPARATOR
Intervention: Healthy weight control program
Number of subjects: 481
Study 21975593 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing control condition
Number of subjects: 481
Study 21975593 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 481
Study 20132154 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 0
Study 20132154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19468079 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 0
Study 19468079 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 0
Study 19468079 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16510657 — intervention group
Group type: EXPERIMENTAL
Intervention: INT (n = 377)
Number of subjects: 985
Study 16510657 — intervention group
Group type: COMPARATOR
Intervention: FUO (n = 608)
Number of subjects: 985
Study 15570920 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-1 + cisplatin (CDDP)
Number of subjects: 19
Study 15570920 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP)
Number of subjects: 19
Study 15570920 — intervention group
Group type: COMPARATOR
Intervention: TS-1 alone
Number of subjects: 19
Study 15570920 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone
Number of subjects: 19
Study 15570920 — intervention group
Group type: COMPARATOR
Intervention: CPT-11 with CDDP therapy
Number of subjects: 19
Study 10772604 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day naltrexone
Number of subjects: 196
Study 10772604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 10772604 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with intervention
Number of subjects: 196
Study 10772604 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone without intervention
Number of subjects: 196
Study 9310275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol once daily for 8 weeks
Number of subjects: 82
Study 9310275 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard twice daily for 8 weeks
Number of subjects: 82
Study 8325059 — intervention group
Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 14
Study 8325059 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 14
Study 3488184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd-YAG laser photocoagulation
Number of subjects: 33
Study 3488184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 33
Study 3488184 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized group
Number of subjects: 33
Study 3488184 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 33
Study 29492652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortico-spinal excitability measures (resting motor thresholds and motor evoked potentials)
Number of subjects: 18
Study 27106009 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 971
Study 27106009 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 971
Study 25876351 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisting acupuncture at Taichong (LR 3) for 5 minutes (30 seconds manipulation and 30 seconds interval).
Number of subjects: 18
Study 25876351 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture at Taichong (LR 3) for 5 minutes (30 seconds manipulation and 30 seconds interval).
Number of subjects: 18
Study 22572647 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 6
Study 22572647 — intervention group
Group type: COMPARATOR
Intervention: Normal sedentary lifestyle (Control)
Number of subjects: 6
Study 20636965 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 10
Study 20636965 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 10
Study 20636965 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 10
Study 17852760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation treatment (25 hours, across 8 weeks)
Number of subjects: 12
Study 17852760 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 12
Study 16000678 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day)
Number of subjects: 117
Study 16000678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 12093423 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect repellant use in high-risk situations
Number of subjects: 1820
Study 12093423 — intervention group
Group type: EXPERIMENTAL
Intervention: Body checks for ticks after leaving infested areas
Number of subjects: 1820
Study 12093423 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing ticks from pets with bare hands
Number of subjects: 1820
Study 12093423 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for tick bites
Number of subjects: 1820
Study 12198788 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal strings
Number of subjects: 0
Study 12198788 — intervention group
Group type: EXPERIMENTAL
Intervention: Figurative strings
Number of subjects: 0
Study 12198788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsense strings
Number of subjects: 0
Study 7502516 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitor Cilacapril, taken once a day between 7.00 a.m. and 9.00 a.m.
Number of subjects: 945
Study 7502516 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant patients
Number of subjects: 945
Study 1953094 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched intravenous feedings (0.57 g/kg/day, GLN)
Number of subjects: 20
Study 1953094 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (STD)
Number of subjects: 20
Study 7010893 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin, 5000 units every 8 hours for 14 days
Number of subjects: 130
Study 7010893 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as soon as possible after the fracture
Number of subjects: 130
Study 30915569 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (SC)
Number of subjects: 156
Study 30915569 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 156
Study 30915569 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help
Number of subjects: 156
Study 30915569 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire SC program
Number of subjects: 156
Study 30915569 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 156
Study 28610932 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated disinfection with hydrogen peroxide <8% and silver ions
Number of subjects: 0
Study 28610932 — intervention group
Group type: COMPARATOR
Intervention: Manual disinfection with 0.5% sodium hypochlorite solution
Number of subjects: 0
Study 25904755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 312
Study 25904755 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D analogs
Number of subjects: 312
Study 23393182 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant individuals
Number of subjects: 26
Study 23393182 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive individuals
Number of subjects: 26
Study 21542027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg dose of alcohol (cumulative dose 0.8 g/kg)
Number of subjects: 60
Study 21542027 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 60
Study 19244040 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D segmentation and computerized volumetry technique
Number of subjects: 52
Study 19244040 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MR imaging
Number of subjects: 52
Study 17578786 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women with TB
Number of subjects: 715
Study 17578786 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected women without TB
Number of subjects: 715
Study 17578786 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of mothers with TB
Number of subjects: 715
Study 17578786 — intervention group
Group type: COMPARATOR
Intervention: Infants of mothers without TB
Number of subjects: 715
Study 17578786 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with incident TB
Number of subjects: 715
Study 17578786 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of women with incident TB
Number of subjects: 715
Study 15137555 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (low intensity, mean visits Oxford = 4, Bradford = 5)
Number of subjects: 264
Study 15137555 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 264
Study 11247684 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic adhesive drapes
Number of subjects: 298
Study 11247684 — intervention group
Group type: COMPARATOR
Intervention: No plastic adhesive drapes (control)
Number of subjects: 298
Study 9260367 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (5-10 mg daily, doubled if necessary)
Number of subjects: 70
Study 9260367 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50-100 mg daily, doubled if necessary)
Number of subjects: 70
Study 8294169 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (100 mg dose)
Number of subjects: 62
Study 2832287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (0.1 mg/kg body weight)
Number of subjects: 6